Neoadjuvant therapy in resectable pancreatic cancer: A promising curative method to improve prognosis

Figure 1 Overall survival. A: Comparison between NAT group and upfront surgery group; B: Comparison among different arms. Arm A: Upfront surgery (GEM); Arm B: Upfront surgery (PEXG); Arm C: PEXG. GEM: Gemcitabine; PEXG: Cisplatin, epirubicin, capecitabine, and gemcitabine. A: Citation: Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, Buijsen J, Busch OR, Creemers GM, van Dam RM, Eskens FALM, Festen S, de Groot JWB, Groot Koerkamp B, de Hingh IH, Homs MYV, van Hooft JE, Kerver ED, Luelmo SAC, Neelis KJ, Nuyttens J, Paardekooper GMRM, Patijn GA, van der Sangen MJC, de Vos-Geelen J, Wilmink JW, Zwinderman AH, Punt CJ, van Eijck CH, van Tienhoven G; Dutch Pancreatic Cancer Group. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol 2020; 38: 1763-1773. Copyright ©The Author(s) 2020. Published by Wolters Kluwer Health Inc. B: Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R, Pinelli D, Mosconi S, Doglioni C, Chiaravalli M, Pircher C, Arcidiacono PG, Torri V, Maggiora P, Ceraulo D, Falconi M, Gianni L. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial. Lancet Gastroenterol Hepatol 2018; 3: 413-423. Copyright ©The Author(s) 2018. Published by Elsevier.